What started off as basic research 25 years ago has now lead to a successfully approved drug: The entry blocker bulevirtide (brand name Hepcludex, formerly known as Myrcludex B), jointly developed by researchers...

A new study funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) is among the first to suggest that intestinal fungi may contribute to the development of alcoholic liver disease (ALD)....